Psyence Biomedical Ltd. (PBM) Research
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Market snapshot
- Symbol
- PBM
- Price
- $3.15
- Day change
- +1.94%
- Market cap
- $59.9K
- P/E ratio
- 1.77x
- 52-week range
- 1.92-468.35938
- Sector
- Healthcare
- Industry
- Biotechnology
Recent news
- PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story
Psyence Biomedical (NASDAQ: PBM) stock is surging Monday on a broad psychedelic rally and a company-specific ibogaine supply catalyst.
Peer companies
Open Psyence Biomedical Ltd. (PBM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.